key: cord-0993711-jy3kbwlv
authors: Pathak, Lekhika; Gayan, Sukanya; Pal, Bidisha; Talukdar, Joyeeta; Bhuyan, Seema; Sandhya, Sorra; Yeger, Herman; Baishya, Debabrat; Das, Bikul
title: Coronavirus activates an altruistic stem cell mediated defense mechanism that reactivates dormant tuberculosis: implications in COVID-19 pandemic
date: 2021-04-19
journal: Am J Pathol
DOI: 10.1016/j.ajpath.2021.03.011
sha: 11aaba6e0e9c58b9a7600c267594462046c56ea1
doc_id: 993711
cord_uid: jy3kbwlv

We postulate that similar to bacteria, adult stem cells may also exhibit an altruistic defense mechanism to protect their niche against external threat. Here, we report mesenchymal stem cell (MSC) based altruistic defense against a mouse model of coronavirus, murine hepatitis virus-1 (MHV-1) infection of lung. MHV-1 infection led to reprogramming of CD271+MSCs in the lung to an “enhanced stemness” phenotype that exhibits altruistic behavior as per our previous work in human embryonic stem cells. The reprogrammed MSCs exhibited transient expansion for two weeks followed by apoptosis, and expression of stemness genes The conditioned media of the reprogrammed MSCs exhibited direct anti-viral activity in an in vitro model of MHV-1 induced toxicity to type II alveolar epithelial cells by increasing their survival/proliferation and decreasing viral load. Thus, the reprogrammed MSCs can be identified as altruistic stem cells (ASCs) which exert a unique altruistic defense against MHV-1. In a mouse model of MSC mediated Mycobacterium tuberculosis (Mtb) dormancy, MHV-1 infection in the lung exhibited 20-fold lower viral loads than the Mtb-free control mice on the third week of viral infection, and also exhibited 6-fold increase of ASCs, thereby enhancing the altruistic defense. Notably, these ASCs exhibited intracellular replication of Mtb, and their extracellular release. Animals showed TB reactivation suggesting that dMtb may exploit ASCs for disease reactivation..

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mediated coronavirus disease 2019 (COVID-19) pandemic demonstrates the ability of an emerging virus to create chaos in our modern health care system and a severe strain on the global economics. In the long term, post-pandemic, the SARS-CoV-2 might activate dormant bacterial infections. As per prior history, tuberculosis is one of the key bacterial infections affected by viral pandemics (1) (2) (3) (4) (5) . Strikingly, one quarter of the world population is already infected with dormant tuberculosis (TB) (https://www.who.int/news-room/fact-sheets/detail/tuberculosis). If SARS-CoV-2 infects these dormant TB populations, it may cause severe impact in global health and economics by causing both COVID-19 and dormant TB reactivation. Thus, there is an urgent need to study the association of COVID-19 with dormant TB reactivation to avoid a later global TB pandemic. Viral infection such as the influenza virus or SARS-CoV-1 is known to cause transient immune suppression that leads to reactivation of dormant bacterial infection (6) (7) 4) . In 1918, the Spanish flu pandemic led to the rise of pulmonary TB incidence (2, 8) . Influenza in patients with TB had the highest death rate (8-9). In the year 2009 during the influenza A (H1N1) pandemic, a worse prognosis of influenza was observed in patients with TB or MDR/TB (10-11).

Interestingly, SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV) infected patients were reported to develop pulmonary TB (PTB) (5, 4) . Using a mouse model, an earlier study showed that influenza A virus cause rapid development of PTB lesions (12) and an increase in the mycobacterium load in the liver (13) . Another mouse model of Influenza A virus and Mtb co-infection led to enhanced Mtb growth by a type-I IFN signaling pathway (6) .

However, severe inflammation in the lung is a common outcome of coronavirus infection (14) , a J o u r n a l P r e -p r o o f symptom which is also commonly observed in TB patients (15) . Thus, it is possible that coronavirus infection causing inflammation may also lead to reactivate dormant Mtb in the lung, which has not yet been studied.

We have been investigating TB dormancy in the adult stem cell niches (16) (17) (18) . These stem cells reside in the bone marrow (BM) niche (19) and in the area of inflammation (20) . We have identified a rare fraction of cells in the BM, the CD271+BM-mesenchymal stem cells (CD271+BM-MSCs) as the potential niche for dormant Mtb in mice and in successfully treated TB patients (17) . In this stem cell niche, Mtb remains dormant, maintaining reactivation potential. Importantly, we have developed a mouse model of stem cell mediated Mtb dormancy (17) . Briefly, streptomycin dependent mutant 18b strain infected mice exhibit lung infection following 3 weeks of streptomycin treatment. These mice develop granulomas, and also acquire humoral immunity against the bacteria. Following streptomycin starvation for 6 months, the bacteria acquire a non-replicating status. Mostly, these bacteria can be detected in the CD271+MSCs of BM, but a few are also present in the CD271+MSCs of lung (17) .

Furthermore, Mtb harboring CD271+MSCs reside in the hypoxic niche of BM (18) . Notably, in this model, the significant increase of Mtb-CFUs in the non-CD271+MSC compartment of lung can be utilized as a sign of Mtb reactivation. Additionally in this model, the potential reprogramming of the CD271+MSCs to enhanced stemness phenotype having altruistic behavior (21) (22) can also be studied. Briefly, the "enhanced stemness" is a transient phenotype of stem cells characterized by their ability to not only maintains stemness, but also secret cytoprotective agents during extreme oxidative stress or inflammation (21) (22) . We have characterized the "enhanced stemness" phenotype by exposing human embryonic stem (ES) cells to the microenvironment of oxidative stress. In such hostile microenvironment, some of the ES cells J o u r n a l P r e -p r o o f underwent enhanced stemness reprogramming by activating a HIF-2alpha stemness pathway that altered the p53/MDM2 oscillation to a transient state of low p53. The low p53 state permits these cells to maintain a state of enhanced stemness (state of self-renewal and self-sufficiency) in the microenvironment oxidative stress (22) . While in such hostile microenvironment naive stem cells usually undergo differentiation/apoptosis (21) , the reprogrammed ES cells not only maintained stemness, but also self-renew. Thus, these reprogrammed ES cells gained fitness. However, instead of becoming the dominant subpopulation, these cells sacrificed their self-fitness to enhance the fitness of neighboring cells under stress by secreting glutathione, an intracellular antioxidants that cells do not actively secret. Moreover, the cultured supernatant of these reprogramed ES cells defended hematopoietic and mesenchymal stem cells from oxidative stress induced differentiation/apoptosis. We have considered this as an altruistic behavior, a form of stem cell altruism (23) , as these glutathione secreting ES cells sacrificed their newly acquired fitness by returning to basal state of p53/MDM2 oscillation leading to p53 mediated apoptosis/differentiation (22) . Hence, these transient stem cells acquiring "enhanced stemness" phenotype could be termed as altruistic stem cells (ASCs) in contrast to competitive stem cells which eliminate weak neighbors during stress (21, 24, 25) . The underlying significance of further studying stem cell altruism is it is equivalent to an innate defense mechanism of cytoprotection, because similar to microbial altruistic defense against stress (26, 27) , ASC mechanisms may also have evolved as a potent stem cell defense of cytoprotection from stressful microenvironment induced differentiation/apoptosis (21) . Developing an experimental model to study ASC based defense will strengthen our growing understanding of stem cell niche defense against pathogen invasion, and also provide novel insight about how pathogens such as dMtb may hijack this defense for their own benefit. Here we hypothesize that following viral infection, lung MSCs J o u r n a l P r e -p r o o f present in the alveolar stem cells niche (28-29) may also exhibit altruistic defense by reprogramming to ASCs. The dormant Mtb hiding in the intracellular compartment of these MSCs may then exploit the ASC reprograming for TB reactivation (25) .

Therefore, using this mouse model of stem cell mediated Mtb dormancy we sought to find out, if coronavirus can reactivate dormant Mtb (dMtb) by inducing MSC to ASC reprogramming. We are using a mouse coronavirus strain, the murine hepatitis virus -1 (MHV-1) that represents clinically relevant human coronavirus SARS-CoV-1 infection (30) (31) (32) . MHV-1 infection causes acute lung inflammation by inducing acute respiratory infection (ARI) within 2-4 days in C57BL/6 mice by increasing viral load. Animals exhibit an elevated level of proinflammatory cytokines such as TNF-alpha during 2-14 days post-infection (30, 33) and then fully recover (30) . Therefore, this MHV-1 infected C57BL/6 mouse could be utilized for Mtb reactivation study.

Here, we demonstrate that MHV-1 infection causes dMtb reactivation in the mouse model of stem cell mediated Mtb dormancy. Furthermore, we found that MHV-1 reprograms the CD271+MSCs to an "enhanced stemness" or ASC phenotype, and culture supernatant of these reprogrammed MSCs enhance the survival/proliferation of MHV-1 infected type II alveolar epithelial (ATII) cells. After two weeks of expansion in the MHV-1 infected lung, these reprogrammed MSCs activated p53 upstream genes involved in apoptosis/differentiation, and underwent apoptosis thus sacrificing self-fitness while enhancing the fitness of the alveolar epithelial cells, a behavior akin to ES cells exhibiting "enhanced stemness" or ASC phenotype.

Thus, our findings may facilitate the study of proposed ASC mediated altruistic defense of stem cell niche (21, 34, 25) . The remarkable significance of this study is that although, MHV-1 J o u r n a l P r e -p r o o f infection causes dMtb reactivation, it also activates an ASC based innate defense mechanism against the virus and that could be further explored to develop therapeutics to target coronavirus. (30, 32) to develop mice model of reactivation. In a separate experiment, streptomycin treated mice were also treated with immunosuppressive agents dexamethasone (0.08mg/day, 6 times a week) or amino guanidine (2.5% wt/vol in drinking water) to cause dMtb reactivation (35) . The treated mice were observed for stipulated period of time, and then sacrificed to collect lung tissues. The Mtb-CFU of lung was evaluated for Mtb reactivation.

Isolation and culture of CD271+MSCs: The mice lung tissues were dissociated using collagenase/lipase and then, cells were subjected to magnetic sorting to isolate CD271+MSCs as explained previously (17) (18) . Briefly, CD45-cells were magnetically sorted using Ter119/CD45-depletion kit (#19771; Stem Cell Technologies, Vancouver, BC). Next, the CD45-cells were subjected to magnetic sorting for isolation of CD271+ cells. First, mouse hours to obtain the conditioned media.

Forming Unit (CFU) assay: This was carried out as previously described (17) (18) .

For the whole lung Mtb-CFU, the lung tissue were aseptically removed from sacrificed mice and homogenized in PBS with 0.05% Tween 80, then subjected to CFU assay (18) . For the Mtb-CFU assay of immunomagnetically sorted cells, cells were isolated by dissociating lung tissue using Collagenase/Lipase (17) . The pellet was lysed with 1 ml of 0.1% Triton X-100 for 15 min, vortexed for 30 seconds, and serial 10-fold dilution was prepared in Middlebrook 7H9 broth. The diluted whole lung or cell lysate were then separately plated on Middlebrook 7H10 agar plates (BD Bioscience, #295964) along with streptomycin (50µg/ml) for the growth of m18b strain.

The agar plates were incubated for 3-4 weeks at 37 o C and 5% CO2 and CFUs were counted.

CFUs were plotted as the means of log10 CFUs per lung or per 10 7 cells. qPCR assay: To isolate the mRNA from bacterial infected CD271+MSCs, we used the µMACS TM technology (Miltenyi Biotec, Bergisch-Gladbach, Germany) as described previously (17) . Briefly, the mRNA is isolated in a magnetic column using super paramagnetic Oligo (dT) Microbeads which target the poly RNA tail of mammalian RNA. The mRNA gets attached to the magnetic column, whereas the bacterial and stem cell DNA remained in the passed-through lysate. Then, the mRNA was converted to cDNA in a heated magnetic bar as per manufacture instruction and cDNA was subjected to qPCR analysis using the TaqMan Gene expression assay Biotech, Bergisch-Gladbach, Germany). RNA quantification was done using the ∆∆ Ct method by using the SDS software, version 2.2.1 (17) . The following TaqMan primers were used: Mtb strain followed by 6 months of streptomycin starvation, or control group -25-26 weeks old healthy mice) were intranasally infected with 5000 PFUs of MHV-1 per mouse (30, 32) . Briefly, animals were anesthetized with ketamine intraperitoneally and then 50 µl of MHV-1 in PBS was administered intranasally; this dose is known to cause ARI in this strain of mice (31, 33) .

Evaluation of lung infection was done by viral load study and measurement of TNF-alpha on day 0 and 6 as described (30, 33) .

This assay was performed as previously described (36) . In specific time period, animals were euthanized, and the whole lungs were harvested. The lung tissue was homogenized as described (17) , and the supernatant was stored at -80°C prior to further analysis. One day prior to the formation of the PFU assay, L2 cells were seeded so that the cell density could reach confluence on the day of PFU assay. The serial dilution of lung homogenate derived supernatant was loaded on the L2 monolayer cells and incubated for one J o u r n a l P r e -p r o o f hour at 37˚C. The inoculum was removed, and it was over layered with methylcellulose media and incubated for 48 hr at 37 ˚C. The plaques were then counted and the virus titer was calculated using the following formula: titer (PFU/ml) = [(number of plaques/well)/(volume of inoculum/well)] x dilution factor.

Enzyme Linked Immunosorbent Assay (ELISA) for TNF-alpha evaluation: This was done by using an Elisa Kit (#MTA00B) of R&D Systems (Minneapolis, MN) as described previously (22) . Briefly, whole lungs were harvested and homogenized in DMEM/F12 medium supplemented with protease inhibitor mix (Sigma Aldrich). Lung homogenates were centrifuged, and 50 µl of supernatant was added to the wells of the ELISA plate, covered and incubated at room temperature for 2 hours. Each well was aspirated and washed for five times as mentioned in the kit. 100 µl of Mouse TNF-alpha conjugate to horseradish peroxidase was added to each well and covered with an adhesive strip. It was then incubated for 2 hours at room temperature and then aspirated and washed. The plates were developed for 30 minutes using 100 µL of tetramethylbenzidine plus hydroegen peroxide. Plates were read at 450 nm using iMark™ Microplate Absorbance Reader (Biorad, Gurgaon, India). Cellular caspase-3/7 assay: The caspase-3/7 activity assay was done as previously described (22, 37) . Briefly, the day-8 and day-20 CD271+ MSCs were isolated from the MHV-1 alone (with strepto), dMtbMHV-1, dMtb alone (with strepto) and streptomycin alone (control mice treated with streptomycin) group (n=5 for each group). Then, isolated CD271+MSCs were cultured (2x10^4 cells/ml) in serum free DMEM media for 8 hours and subjected to a colorimetric assay of caspase 3/7 activity (22, 37) .

In vitro cytoprotection assay against MHV-1 infection: The type II alveolar epithelial (ATII) cells of healthy C57BL/6 mice were first isolated as previously described (38) by isolating CD45-, and EPCAM+ cells using immunomagnetic sorting (39) . The isolated cells were cultured in the 70% rat tail collagen (Sigma) and 30% Matrigel (BD Biosciences) coated 6-well plates (2x10^5 cells/well) using DMEM/F12/10% FBS and 10ng/ml mouse keratinocyte growth factor with penicillin/streptomycin antibiotics. The cells were infected with MHV-1 with a MOI of 1:5 as described (38) and then treated for 48 hours with the CM obtained from the lung CD271+MSCs collected from the three groups (dMtb alone, MHV-1 alone and the dMtbMHV-1 group). The conditioned media (CM) was collected from in vivo CD271+ MSCs by a previously described method (22) , where the isolated CD271+MSCs (1x10^7 cells/ml) were cultured in vitro for 24 hours, and then CM was filtered through a 0.2 micron filter. The filtered CM was added to ATII cells. After 48 hours of growth, cytoprotection was measured by the reduction in viral load (viral plaque assay), cell survival (trypan blue assay) and cell proliferation (alamar blue assay) as previously described (40, 41) . For the cell proliferation assay, the viral infected cells were continuously grown for 6-days, and then alamar blue assay was performed every alternate day to measure proliferation as described (37) .

Statistics: Statistical analysis was carried out using GraphPad Prism version 4.0 (Hearne Scientific Software, Chicago, IL, USA). Student's t test was used for comparisons with Newman-Keul post hoc test. The gene expression was analyzed using One-Way ANOVA with Dunnett's post-hoc test. Data are expressed as means ± SEM; *p<0.05, **p< 0.01, ***p<0.001 and ****p<0.0001.

We reasoned that MHV-1 infection may reactivate dMtb intracellular to MSCs in the lung. To test this hypothesis, MHV-1 (5x10^3 PFU) was intranasally administered to C57BL/6 mice (n=25) (30, 32) , having lung CD271+ MSCs, that contain streptomycin-dependent mutant Mtb strain of 18b in non-replicating dormant state for 6 months ( Figure 1A ) (17, 42) .

Simultaneously, mice were also injected with streptomycin as the mutant 18b strain requires the antibiotic to replicate (42) . Study was ended after three weeks, because (i) three weeks of streptomycin is sufficient to establish lung infection (17) Therefore, next we compared the MHV-1 induced reactivation of the dMtb with dexamethasone, or aminoguanidine. These have been found to reactivate dMtb in a drug-induced Cornell model by suppressing the immune system (35) . To compare the reactivation of MHV-1 versus these immunosuppressive agents, dMtb harboring mice were treated with either of these two drugs and streptomycin daily for a month, then the lung Mtb-CFUs were quantified. Next, the Mtb-CFU of these two drugs treated mice with the Mtb-CFU obtained from one-month post-MHV-1 infected mice were compared. We found that Mtb-CFUs increased by only 3-4-fold (p=0.06; n=4) following either dexamethasone or aminoguanidine treatment, which was 400-fold lower than the MHV-1 infection group (p<0.0001, n=4; Figure 1D ). Thus, MHV-1 infection was superior to dexamethasone or aminoguanidine to induce reactivation in our model of dMtb. Our results also indicate that mechanisms other than immunosuppression may underlie MHV-1 infection mediated disease reactivation.

In this mouse model of Mtb dormancy, dMtb remains dormant in CD271+MSCs of bone marrow and lung. We hypothesized that during dMtb reactivation, the bacteria transfer from MSCs to non-MSC compartments in the lung (17) . Thus, we analyzed the lung CD271+MSCs for intracellular Mtb replication and release into the extracellular space. Lung CD271+MSCs were obtained by immunomagnetic sorting of CD271+/CD45-mononuclear cells after a stipulated time period of MHV-1 infection. We have already confirmed 90% purity of these immunomagnetic sorted CD271+MSCs by flow cytometry as previously described (17, 18) Viable cell count was obtained by trypan blue to evaluate expansion of these cells in vivo in the stipulated time period. The dMtb group served as a control. We also studied possible CD271+MSCs expansion in mice infected with MHV-1 to evaluate a potential effect of this virus on MSCs of lung. Next, the sorted cells were cultured in serum-free media for 8 hours to evaluate both the intracellular and the extracellular release of Mtb by measuring Mtb-CFUs in the cell pellet and supernatant respectively. We found that the dMtbMHV-1 group showed a transient 12-fold (p<0.001, Figure 2A ) expansion of CD271+MSCs between day-0 and 8.

Strikingly, we also found that MHV-1 infection alone group exhibited a 4.5-fold (p<0.01) J o u r n a l P r e -p r o o f expansion of CD271+MSCs between the same period; however, the expansion was 6-fold lower than the dMtbMHV-1 group (Figure 2A) . Whereas, the dMtb alone group showed no expansion of the MSCs (Figure 2A) . Notably, in the dMtbMHV-1 group, along with MSC expansion, there was a corresponding 27-fold (p<0.001; Figure 2B 

The MHV-1 infection induced transient expansion of lung CD271+MSCs in both Mtb harboring and control animal group encouraged us to study the underlying molecular mechanism of expansion. We considered that MHV-1 infection may activate an altruistic stem cell (ASC) based innate defense mechanism that we previously characterized in human embryonic stem cells (hESCs) (22) , and also in mesenchymal stem cells (MSCs) (18) . Briefly, when a clone of stem cells such as hESCs cell colony is threatened by hypoxia/oxidative stress induced differentiation/apoptosis, a few of these cells reprogram to an "enhanced stemness" phenotype J o u r n a l P r e -p r o o f capable of not only surviving the stress, but also protecting the rest of the clone from the hypoxia/oxidative stress. This phenotype is characterized by distinct gene expression associated with HIF-2alpha stemness pathway (22, 37) , and rapid expansion of the reprogrammed cells.

These cells continue to maintain enhanced stemness phenotype for the next two weeks, and then activate p53 to undergo differentiation/apoptosis. During the expansion period, these cells exhibit altruistic behaviors by secreting cytoprotective agents such as glutathione that enhance the fitness of the rest of the hES cells. Thus, we characterized stem cells undergoing "enhanced stemness" reprogramming (22) and termed these cells as Altruistic Stem Cells (ASCs) (21, 22) .

Interestingly, we have identified circulating MSCs having ASC like characteristics (24) using defined criteria (34) ( Figure 3A ) in human subjects with cancer (24) suggesting the clinical significance of ASCs. We speculate that this ASC reprogramming may function as a putative innate defense system against invading pathogens that threaten the integrity of the stem cells residing in their niches (34) . Thus, our findings of MHV-1 mediated transient expansion of CD271+MSCs may be part of the ASC defense mechanism against the virus. To investigate this possibility, we first studied the real time PCR (qPCR) expression of genes associated with enhanced stemness phenotype (HIF-1alpha, HIF-2alpha, Sox2, Oct4, Nanog, ABCG2, MDM2, GCL, p53, and p21) in the immunomagnetically sorted day-8 CD271+MSCs of MHV-1 alone and dMtbMHV-1 mice that showed expansion of the MSCs (Figure 2A ). The dMtb alone (dMtb mice treated with streptomycin, but not infected with MHV-1), dMtb minus streptomycin (not treated with streptomycin and MHV-1) and streptomycin alone (control mice with streptomycin treatment) served as controls. We also evaluated the expression of genes expressed by MSC (CD73, CD44, and Sca-1) and hematopoietic (CD45) cells. Results are shown in Figure 3 B-C.

We first confirmed that in the CD271+ MSCs of dMtb mice, HIF-1alpha, ABCG2, Sca-1 and J o u r n a l P r e -p r o o f MSC related genes CD44, CD271 and CD73 remained highly expressed ( Figure 3B ) as consistent with our previous findings (17, 18) . Addition of streptomycin treatment showed 1.6fold higher expression of HIF-1alpha (p<0.05; Figure 3B ) in the CD271+ MSCs of dMtb mice (dMtb alone), but had no effect in the control mice (Streptomycin alone). Importantly, MHV-1 infection in streptomycin alone (MHV-1 alone) and dMtb alone group (dMtbMHV-1) led to 3-7 fold marked induction of genes associated with enhanced stemness phenotype in the CD271+ MSCs ( Figure 3C ). Interestingly, in the dMtbMHV-1 group, several enhanced stemness phenotype or ASC reprogramming related gene (Oct4, GCL and ABCG2) expression was increased by 2-3-fold (p<0.05; Figure 3C ) compared to MHV-1 alone group. We further characterized the stemness of these CD271+MSCs and indeed, these cells expressed the MSC markers; CD73, CD44, and Sca-1 whereas CD45 was not expressed ( Figure 3C ). Thus, these findings suggest that MHV-1 infection led to ASC reprogramming of CD271+MSCs, and this reprogramming was also seen in the dMtb harboring mice, when infected with MHV-1. Further confirmation of the ASC reprogramming was obtained by demonstrating increased up-regulation of p53-upstream genes involved in apoptosis such as bax, p21 and PUMA, and down-regulation of survival genes such as HIF-2alpha on day-20 ( Figure 3D) . We also noted that the expression of Sca-1 was down regulated in these cells on day 20 ( Figure 3D ), suggesting differentiation.

Thus, it appears that the transiently expanded CD271+ MSCs underwent differentiation and apoptosis on day-20 of MHV-1 infection, which we confirmed by performing a caspase 3/7 activity assay for apoptosis (22, 37) (Figure 3E ). We also noted that streptomycin treatment either in control (streptomycin alone) or in dMtb mice (dMtb alone) did not induce apoptosis of CD271+ MSCs ( Figure 3E ). Activation of p53 upstream genes and associated apoptosis on day-J o u r n a l P r e -p r o o f infected CD271+MSCs against MHV-1.

We confirmed this ASC based defense against MHV-1 mediated viral load and cellular toxicity in an in vitro viral infection assay ( Figure 4A ). We demonstrated that the MHV-1 alone group derived conditioned media (CM) of CD271+MSCs on day-8 were capable of exhibiting significant 2-4 fold cytoprotection of type II lung alveolar epithelial (ATII) cells against MHV-1 infection ( Figure 4B-E) , providing evidence of ASC mediated defense against MHV-1 ( Figure   5 ). Notably, dMtb presence significantly boosted this ASC based defense against MHV-1 in the in vitro viral infection assay, as the viral load was reduced by 3-fold ( Figure 4B ), while survival and proliferation of the ATII cells was increased by 2 and 4 fold respectively in the dMtb MHV-1 versus MHV-1 alone group ( Figure 4C and E) . These results further strengthen the proposed mechanism of ASC mediated niche defense against MHV-1 and boosting of this defense in the dMtb harboring mice.

The COVID-19 caused by SARS-CoV-2, has created a global pandemic associated with substantial mortality and morbidity. Notably, a significant number of infected individuals have recovered. However, evidence for a possible host defense or anti-viral mechanism against the virus has not yet been identified. Currently, several vaccines have been approved to combat the pandemic (43, 44) , although the efficacy of these vaccines may be compromised due to rapid mutation of the virus. In this context, it is important to understand the host defense mechanism against this disease for the development of better vaccine and or treatment. Using a mouse coronavirus model, we demonstrate that lung MSCs activate a potential ASC based defense mechanism against the virus and this defense mechanism is further enhanced by dMtb residing To study the interaction of dormant Mtb niche with coronavirus infection in the lung, we used streptomycin dependent auxotrophic strain of mutant 18b mediated mouse model, where dMtb can be isolated from the CD271+ MSC compartment of lung following 6 months of streptomycin starvation (17, 42) . In this mouse model, re-addition of streptomycin for 4 weeks after 6 months of withdrawal did not lead to dMtb reactivation as the lung Mtb-CFUs in the non-MSC compartment did not significantly increase. Although a 20-fold increase in Mtb-CFUs in non-MSC compartment was observed during first two weeks of streptomycin treatment, it was transient as Mtb-CFUs gradually decreased in the next two weeks. Thus, the cumulative increase of Mtb-CFUs was only 3-fold (p>0.05; Figure 1D ), which is not enough to cause TB reactivation in lung (35) . Whereas, infection with MHV-1 in the presence of streptomycin caused sustained increase of Mtb-CFUs in the non-MSC compartment of the lung by 3,500-fold ( Figure 1D ), suggesting lung TB reactivation as defined previously (35) . Importantly, increase of Mtb-CFUs Altruistic behavior has been reported in bacteria as a defense strategy against antibiotic exposure; a few members of bacteria sacrifice self-fitness to enhance group fitness, similar to kin selection noted in biological altruism (26, 45, 27) . Whether the stem cells exert similar altruistic behavior as a defense strategy to protect their niche is not yet clear. We are proposing that stem cells exert altruistic behavior by the mechanism of stem cell altruism (22, 34, 25) . The stem cell altruism could be defined as a fitness-defense mechanism that protects weak neighbors in their niche (34) in contrast to stem cell competition, which is a fitness-sensing mechanism that eliminates weak neighbors in the niche (46) . Previously, we characterized "enhanced stemness reprogramming" as a form of stem cell altruism that increases the fitness of surrounding tissues during the process of tissue regeneration (22, 47) . Further, we conceptualized the idea of altruistic stem cells in the context of stem cell niche based innate defense mechanisms (17, 18, 34) . The Thus, it appears that we have identified putative MSC derived ASCs. Hence, we suggest that ASC mediated anti-viral defense system for lung alveolar stem cell niche may be harnessed to develop novel therapeutic strategies against COVID-19. Though, we do acknowledge the limitation of our findings. There are future researches required to validate the altruistic nature of these reprogrammed CD271+ MSCs or ASCs, including the demonstration of potential activation of HIF-2alpha stemness pathway, secretion of cytoprotective biomolecules that may act as a biofilm to shield the epithelial stem cell niche from the toxic effects of the virus, and inflammation. Furthermore, additional studies are required to assess the potential role of CD271+ ASCs to defend the lung alveolar stem cell niche (28, 29,48) including potential secretion of antimicrobial peptides such as cathelicidin hCAP-18/ LL-3 (49) or microRNA (50) (51) (52) . Taken together, we suggest that our model of pathogen-induced enhanced stemness reprogramming of J o u r n a l P r e -p r o o f CD271+ MSCs in the lung may serve as model to study the stem cell altruism, and its role in pathogen/host interaction (25) .

The adaptive immune response can play an important role in infection control of MHV-1 in C57BL/6 mice (32), however this does not solely account for the resistance displayed by this mouse strain against the viral infection associated morbidity and mortality (31) . So far in this MHV-1 infection model and immune response, the role of ASC based innate immunity has not been evaluated. Our findings indicate that MHV-1 may induce an ASC mediated defense, as the conditioned media of the CD271 ASCs obtained from the MHV-1 infected mice exhibited direct anti-viral activities. Further work is necessary to find out a memory component in the ASC defense. The memory component of innate immunity is also known as the trained immunity, which has recently being demonstrated in stem cells (48, 53) . For example, hematopoietic stem cells may undergo cell intrinsic changes including metabolic as well as epigenetic modifications to remember pathogenic insult (48, 53) and BCG-mediated trained immunity against viral infection (54) . Although, trained immunity of MSCs has not yet been demonstrated, our ongoing work indicates that dMtb harboring MSCs may exhibit a HIF-1alpha dependent trained immunity (55) ; HIF-1alpha is a mediator of trained immunity (48, 53) . We suggest that our findings of ASC mediated innate immunity may play a key role in trained immunity. In this context, our findings of 2-fold increase of HIF-1alpha and transient rise of Mtb-CFUs in the dMtb mice following streptomycin treatment ( Figure 3B ) may indicate the triggering of trained immunity in the high HIF-1alpha expressing CD271+ MSCs following streptomycin-induced dMtb reactivation. Future work is required to find out if this putative trained immunity could be involved in the decline of Mtb-CFUs in the dMtb alone mice following initial increase in the first J o u r n a l P r e -p r o o f 

In contrast, our findings suggest that Mtb reactivation reduces the viral load in lung. However our study is based on a mouse model, which needs to be confirmed using human clinical samples. Therefore, we are currently working on COVID-19 subjects to find out Mtb reactivation in the lung. We are also studying the presence of circulating ASC in these subjects as potential evidence for SARS-CoV-2 mediated ASC defense mechanism by adopting a method

In summary, we found that MHV-1 infection induces dMtb loaded MSCs to reprogram to

ASCs, thus activating the ASC defense mechanism and diminishing the MHV-1 infection

Knowledge of immunity to SARS-CoV2 is still at a preliminary stage. Thus, our study may help in understanding how MSCs inducing ASC defense mechanism will help in combating the viral load in the host

The Impact of Influenza and Tuberculosis Interaction on Mortality Among Individuals Aged >/=15 Years Hospitalized With Severe Respiratory Illness in South Africa

The relationship between tuberculosis and influenza death during the influenza (H1N1) pandemic from 1918-19

Influenza and tuberculosis co-infection: A systematic review. Influenza Other Respir Viruses

Severe acute respiratory syndrome and pulmonary tuberculosis

Middle East Respiratory Syndrome Coronavirus and Pulmonary Tuberculosis Coinfection: Implications for Infection Control

A: Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway

Tuberculosis as a Risk Factor for 1918 Influenza Pandemic Outcomes

Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa

Coordinator) and Dennis Falzon (Medical Officer), Stop TB Department, World Health Organisation

Pandemic Influenza (H1N1) and Mycobacterium tuberculosis Co-infection

THE ENHANCING EFFECT OF CONCURRENT INFECTION WITH PNEUMOTROPIC VIRUSES ON PULMONARY TUBERCULOSIS IN MICE

Interactions between T cells responding to concurrent mycobacterial and influenza infections

Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections

Inflammation in tuberculosis: interactions, imbalances and interventions

Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment

A: CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis

Preclinical and Clinical Evidence of Mycobacterium tuberculosis Persistence in the Hypoxic Niche of Bone Marrow Mesenchymal Stem Cells after Therapy

Human bone marrow mesenchymal stem cells in vivo

Tracking inflammation-induced mobilization of mesenchymal stem cells

Altruistic stem cells and cancer stem cells

HIF-2alpha suppresses p53 to enhance the stemness and regenerative potential of human embryonic stem cells

The Science Behind Squalene: The Human Antioxidant. Toronto, Canada: stem cells to resist therapy, and enhance tumorigenic potential of non-tumorigenic cells

Abstract nr 920

Initiation of Post-Primary Tuberculosis of the Lungs: Exploring the

Secret Role of Bone Marrow Derived Stem Cells. Front Immunol

Altruistic defence

Social evolution theory for microorganisms

Concise review

Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors

Therapeutic Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Acute Lung Injury Mice. Sci Rep

Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice

T cell epitope specificity and pathogenesis of mouse hepatitis virus-1-induced disease in susceptible and resistant hosts

Protective and pathologic roles of the immune response to mouse hepatitis virus type 1: implications for severe acute respiratory syndrome

In vitro Culture of Naive Human Bone Marrow Mesenchymal Stem Cells: A Stemness Based Approach

Reactivation of latent tuberculosis: variations on the Cornell murine model

Coronaviruses: propagation, quantification, storage, and construction of recombinant mouse hepatitis virus

HIF2alpha Stemness Pathway via Nanog and Sox2 to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer Cells

Differentiated phenotypes of primary murine alveolar epithelial cells and their susceptibility to infection by respiratory viruses

Oral cancer stem cells modulate Fusobacterium nucleatumto acquire the capability to induce tumor stemness switch

Abstract nr

Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. BMC Cancer

iodobenzylguanidine is selectively radiotoxic to neuroblastoma cells at concentrations that spare cells of haematopoietic lineage

Unique model of dormant infection for tuberculosis vaccine development

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

COVID-19 Vaccine: A comprehensive status report

Bacterial charity work leads to population-wide resistance

Cell Competition and Its Role in the Regulation of Cell Fitness from Development to Cancer

HIF-2α -a mediator of stem cell altruism? Stem Cell Res Ther

Two to Tango: Dialog between Immunity and Stem Cells in Health and Disease

Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37

Exosomal MicroRNAs Derived From Umbilical Mesenchymal Stem Cells Inhibit Hepatitis C Virus Infection

Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model

Mesenchymal stem cells detect and defend against gammaherpesvirus infection via the cGAS-STING pathway

Defining trained immunity and its role in health and disease

BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity

Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity